Metraipolis › archive › dc_6003d57008eb

Budesonide/formoterol fumarate dihydrate versus budesonide with a novel suspension technology for uncontrolled asthma: phase 3 VATHOS study — Europe PMC PMID:42741605

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42741605
DOI
10.1183/23120541.01817-2025
License (as archived)
solo-consultazione
Archived
2026-10-10T02:19:54.353Z
SHA-256 of the archived text
6f5da0f25bd805b9f5cbcb573bc4265f866d824e39cf4a19782a2e046e12f9fa
Stable URL of this page
https://metraipolis.com/documento/dc_6003d57008eb

How to cite

Budesonide/formoterol fumarate dihydrate versus budesonide with a novel suspension technology for uncontrolled asthma: phase 3 VATHOS study — Europe PMC PMID:42741605 — Europe PMC (en), https://europepmc.org/article/MED/42741605 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6003d57008eb (Metraipolis archive dc_6003d57008eb, sha256 6f5da0f25bd805b9f5cbcb573bc4265f866d824e39cf4a19782a2e046e12f9fa)
BibTeX
@misc{dc6003d57008eb,
  title = {Budesonide/formoterol fumarate dihydrate versus budesonide with a novel suspension technology for uncontrolled asthma: phase 3 VATHOS study — Europe PMC PMID:42741605},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42741605},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6003d57008eb; sha256 6f5da0f25bd805b9f5cbcb573bc4265f866d824e39cf4a19782a2e046e12f9fa},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42741605. Agents can read the archived copy with the MCP tool read_document.